This invention relates to novel compounds of the Formula Ik, Im 1 , Im 2 , Im 5 , In 1 , In 2 , In 5 , lo 1 , lo 2 , lo 5 , Ip 1 , Ip 3 , pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11 Î²-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of Cortisol in a cell or the inhibition of the conversion of cortisone to Cortisol in a cell.

Claims

19 · 3 independent · depth 3

19 granted claims

›1.independentA compound represented by the following structural formula:+4

›6.independentA compound represented by the following structural formula:+6

›13.independentA compound represented by the following structural formula:+6

Classifications

4 codes

IPC · International Patent Classification

Section A — Human necessities

A61K31/535

Section C — Chemistry; metallurgy

C07D413/14

USPC · US Patent Classification

514/228.8544/96

Claim changes

Soon

Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this patent are not paired with the granted ones in what we hold.

File wrapper

Pendency

3.5 y

1,285 days filing → grant

Office actions

non-final + final

Responses

3 RCE

Examiner

Kahsay T Habte

art unit 1624 · TC 1600

Law firm

Law firm · Log in to unlock

Citations: 420 back · 0 forward

See the full prosecution history — every USPTO and applicant action on this file, in order.

Term & fees

See the term timeline — pendency span, in-force span, the maintenance fees paid and both computed expiry dates.

Priority chain

1 priority documents

›Priority documents — 1

Type	Document	Date
related publication	US 20120108579 A1	3 May 2012

Validity challenges

See the validity challenges on record — reexaminations, IPRs and PGRs, with their institution decisions and outcomes.

Citations

See every patent this one cites and every patent that cites it back — publication, assignee, and how each one was found.